A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide

被引：0

作者：

Yamaoka, Keiko ^{[1
]}

Nagashima, Shuichi ^{[1
]}

Okada, Nobukazu ^{[1
]}

Sawayama, Nagisa ^{[1
]}

Saito, Shinsuke ^{[1
]}

Takahashi, Manabu ^{[1
]}

Okada, Kenta ^{[1
]}

Endo, Kazuhiro ^{[2
]}

Koizumi, Masaru ^{[2
]}

Sasanuma, Hideki ^{[2
]}

Ebihara, Ken ^{[1
]}

Kasajima, Atsuko ^{[4
,5
]}

Fukushima, Noriyoshi ^{[3
]}

Sata, Naohiro ^{[2
]}

Ishibashi, Shun ^{[1
]}

机构：

[1] Jichi Med Univ, Dept Med, Div Endocrinol & Metab, 3311-1 Yakushiji, Shimotsuke, Tochigi, Japan

[2] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi, Japan

[3] Jichi Med Univ, Dept Pathol, Shimotsuke, Tochigi, Japan

[4] Tohoku Univ, Dept Pathol, Grad Sch Med, Sendai, Miyagi, Japan

[5] Tech Univ Munich, Dept Pathol, Munich, Germany

来源：

CLINICAL CASE REPORTS | 2021年 / 9卷 / 05期

关键词：

hypoglycemia; insulinoma; lanreotide; octrcotidc; somatostatin analog; SOMATOSTATIN ANALOG; THERAPY; AUTOGEL;

D O I：

10.1002/ccr3.4118

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Long-acting somatostatin analogs, including lanreotide slow release (LAN-SR) and octreotide long-acting release (OCT-LAR), can improve hypoglycemia in insulinoma. LAN-SR may be more beneficial in some patients with insulinoma than OCT-LAR.

引用

页数：5

共 19 条

[11] Lloyd RV, 2017, WHO Classification of Tumours, V10
[12] Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas
Marciello, Francesca
Di Somma, Carolina
Del Prete, Michela
Marotta, Vincenzo
Ramundo, Valeria
Carratu, Annachiara
di Roseto, Chiara de Luca
Camera, Luigi
Colao, Annamaria
Faggiano, Antongiulio
[J]. ENDOCRINE, 2014, 46 (03) : 678 - 681
[13] Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
Modlin, I. M.
Pavel, M.
Kidd, M.
Gustafsson, B. I.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (02) : 169 - 188
[14] Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma
Novotny, J
Janku, F
Mares, P
Petruzelka, L
[J]. SUPPORTIVE CARE IN CANCER, 2005, 13 (09) : 760 - 762
[15] Saito S., 2013, JICHI MED SCH J, V36, P107
[16] AGGRAVATION OF HYPOGLYCEMIA IN INSULINOMA PATIENTS BY THE LONG-ACTING SOMATOSTATIN ANALOG OCTREOTIDE (SANDOSTATIN)
STEHOUWER, CDA
LEMS, WF
FISCHER, HRA
HACKENG, WHL
NAAFS, MAB
[J]. ACTA ENDOCRINOLOGICA, 1989, 121 (01): : 34 - 40
[17] Pasireotide for malignant insulinoma
Tirosh, Amit
Stemmer, Salomon M.
Solomonov, Evgeny
Elnekave, Eldad
Saeger, Wolfgang
Ravkin, Yelena
Nir, Kobi
Talmor, Yeela
Shimon, Ilan
[J]. HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2016, 15 (02): : 271 - 276
[18] Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sstS antibodies
Vezzosi, D
Bennet, A
Rochaix, P
Courbon, F
Selves, J
Pradere, B
Buscail, L
Susini, C
Caron, P
[J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152 (05) : 757 - 767
[19] Decreased Insulin Requirements After LAR-Octreotide but not After Lanreotide in an Acromegalic Patient
Susan M. Webb
Emilio Ortega
José Rodríguez-Espinosa
María-Eugènia Mato
Rosa Corcoy
[J]. Pituitary, 2001, 4 (4) : 275 - 278

← 1 2 →